Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...
The Trump administration adds nine midsize pharmaceutical companies, including Teva, UCB, Astellas, and BeOne Medicines to ...
Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer ...
Pharma has more competitive data than ever — and is still getting surprised. Lifescience Dynamics on why intelligence requires human judgment.
BioNTech and Genentech elect to end their Phase II trial of autogene Cevumeran after DSMB identified a numerical overall ...
Pharmaceutical Executive: What is the future of field reps and their relationship with AI? Parth Khanna: Based on our ...
Taken together, Hill's response suggests that restricting access through legitimate compounding channels, without addressing ...
Pharma has more competitive data than ever — and is still getting surprised. Lifescience Dynamics on why intelligence requires human judgment. Pharmaceutical companies have never had access to more ...
DualityBio has licensed its Dupac next-generation ADC payload platform to Genentech, and Teva has entered a stalking horse bid to acquire BioXcel's Igalmi. Dealmaking activity spanned oncology and ...
FDA approved Priovant's Lisraya (brepocitinib) as the first targeted therapy for dermatomyositis, Gilead's Bixlenvo as the ...
With biopharma batch failures averaging every 40 weeks, predictive maintenance and connected monitoring are becoming critical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results